Abstract
Background: Serum undercarboxylated osteocalcin (ucOC) is a biochemical bone marker of vitamin K insufficiency. It had been reported that bone resorption inhibitors tend to decrease the serum ucOC level in patients with primary osteoporosis. In rheumatoid arthritis (RA) patients, these results have never been reported. Aim: We investigated risk factors which could change serum ucOC level in post-menopausal women with RA (no.=100). Subjects and methods: Twenty patients received no bone resorption inhibitor (control), 30 received raloxifene (RLX), while 50 received alendronate (ALN). This cross-sectional study was limited to patients with low RA disease activity (Disease Activity Score-28 ≤3.2). We measured serum ucOC, and the data were analyzed by multivariable analysis, including ucOC and the other variables. Results: Scheffe’s F test demonstrated a significant difference in serum ucOC levels between controls and the RLX group (p<0.01), and between controls and the ALN group (p<0.01). Serum ucOC levels were low in both treated groups. An adjusted multivariate analysis was performed for the variables: bone resorption inhibitor use, serum alkaline phosphatase, glucocorticoid dose, age, estimated glomerular filtration rate and matrix metalloproteinase 3. As a result, serum ucOC inversely correlated with bone resorption inhibitor use (p<0.01) and oral glucocorticoid dose (p<0.01), which were independent risk factors of lowering ucOC. Conclusions: Bone resorption inhibitors and glucocorticoids were independent risk factors for lowering serum ucOC levels in post-menopausal RA patients.
Similar content being viewed by others
References
Booth SL, Tucker KL, Chen H, et al. Dietary vitamin K intakes are associated with hip fracture but not with bone mineral density in elderly men and women. Am J Clin Nutr 2000, 71: 1201–8.
Yaegashi Y, Onoda T, Tanno K, Kuribayashi T, Sakata K, Orimo H. Association of hip fracture incidence and intake of calcium, magnesium, vitamin D, and vitamin K. Eur J Epidemiol 2008, 23: 219–25.
Price PA. Vitamin K-dependent formation of bone Gla protein (osteocalcin) and its function. Vitam Horm 1985, 42: 65–108.
Vergnaud P, Garnero P, Meunier PJ, Bréart G, Kamihagi K, Delmas PD. Undercarboxylated osteocalcin measured with a specific immunoassay predicts hip fracture in elderly women: the EPIDOS Study. J Clin Endocrinol Metab 1997, 82: 719–24.
Shiraki M. Examination of clinical utility of serum ucOC measurement kit with the electrochemiluminescent immunoassay. Medicine and pharmacology 2007, 57: 537–46. [In Japanese]
Hirao M, Hashimoto J, Ando W, Ono T, Yoshikawa H. Response of serum carboxylated and undercarboxylated osteocalcin to alendronate monotherapy and combined therapy with vitamin K2 in postmenopausal women. J Bone Miner Metab 2008, 26: 260–4.
Hozuki T, Imai T, Tsuda E, et al. Response of serum carboxylated and undercarboxylated osteocalcin to risedronate monotherapy and combined therapy with vitamin K(2) in corticosteroid-treated patients: a pilot study. Intern Med 2010, 49: 371–6.
Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988, 31: 315–24.
DAS-SCORE. NL. Home of the DAS: Disease activity score in rheumatoid arthritis. Available at: http://www.das-score.nl/
Genant HK, Wu CY, van Kuijk C, Nevitt MC. Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 1993, 8: 1137–48.
Shiraki M, Yamazaki Y, Shiraki Y, Hosoi T, Tsugawa N, Okano T. High level of serum undercarboxylated osteocalcin in patients with incident fractures during bisphosphonate treatment. J Bone Miner Metab 2010, 28: 578–84.
Roux C. Osteoporosis in inflammatory joint diseases. Osteoporos Int 2010, 22: 421–33.
Momohara S, Okamoto H, Yago T, et al. The study of bone mineral density and bone turnover markers in postmenopausal women with active rheumatoid arthritis. Mod Rheumatol 2005, 15: 410–4.
Aonuma H, Miyakoshi N, Hongo M, Kasukawa Y, Shimada Y. Low serum levels of undercarboxylated osteocalcin in postmenopausal osteoporotic women receiving an inhibitor of bone resorption. Tohoku J Exp Med 2009, 218: 201–5.
Kanazawa I, Yamaguchi T, Yamauchi M, et al. Serum undercarboxylated osteocalcin was inversely associated with plasma glucose level and fat mass in type 2 diabetes mellitus. Osteoporos Int 2011, 22: 187–94.
Canalis E, Mazziotti G, Giustina A, Bilezikian JP. Glucocorticoid-in-duced osteoporosis: pathophysiology and therapy. Osteoporos Int 2007, 18: 1319–28.
Leclerc N, Noh T, Khokhar A, Smith E, Frenkel B. Glucocorticoids inhibit osteocalcin transcription in osteoblasts by suppressing Egr2/Krox20-binding enhancer. Arthritis Rheum 2005, 52: 929–39.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Mokuda, S., Okuda, Y., Onishi, M. et al. Post-menopausal women with rheumatoid arthritis who are treated with raloxifene or alendronate or glucocorticoids have lower serum undercarboxylated osteocalcin levels. J Endocrinol Invest 35, 661–664 (2012). https://doi.org/10.3275/7971
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.3275/7971